BIOVIE INC BIVIW
*W EXP 08/08/203 · Equity WRT · CUSIP 09074F173
- SectorHealth care
- IndustryPharmaceutical Preparations
- HeadquartersCarson City, NV
- FilingsSEC EDGAR
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $0.45.
Trends to Q2 2026
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q3 2025 | 8 |
| Q4 2025 | 9 |
| Q1 2026 | 8 |
| Q2 2026 | 8 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q4 2025 | 4 | 3 |
| Q1 2026 | 1 | 5 |
| Q2 2026 | 2 | 1 |
Biggest buyers
| Warberg Asset Management LLC | Added | +156.8k |
| TWO SIGMA SECURITIES, LLC | Added | +2.8k |
Biggest sellers
| MYDA Advisors LLC | Reduced | -9.1k |
Insider purchases and sales since 1 Apr 2026
Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.
Officers and directors buying vs selling
Number of people, by quarter (10% owners not included)
Numbers
| Quarter | Buying | Bought | Selling | Sold | Sold under a plan |
|---|---|---|---|---|---|
| Q4 2024 | 0 | — | 0 | — | — |
| Q1 2025 | 0 | — | 0 | — | — |
| Q2 2025 | 0 | — | 0 | — | — |
| Q3 2025 | 1 | — | 0 | — | — |
| Q4 2025 | 0 | — | 0 | — | — |
| Q1 2026 | 0 | — | 0 | — | — |
| Q2 2026 | 0 | — | 0 | — | — |
| Q3 2026 | 4 | $49.1k | 0 | — | — |
| Date | Insider | Trade | Value |
|---|---|---|---|
| 2026-08-28 | Palumbo Joseph M Chief Medical Officer | Bought | $10.5k4.8k shares |
| 2026-08-28 | KIM JOANNE WENDY Chief Financial Officer | Bought | $5.5k2.5k shares |
| 2026-08-28 | Chappell Amy Suzon Director | Bought | $1.6k727 shares |
| 2026-08-27 | DO CUONG V President & CEO, director | Bought | $31.6k15.2k shares |
Their holding: how much the trade added to or took from the insider's holding (direct, or the trust or fund named). The same trade is sometimes reported by more than one insider, such as a fund and the director who represents it; totals count it once. A value is left blank where the reported price is far from the market price (usually a typo).
Holders, Q2 2026
| Manager | Shares | Change |
|---|---|---|
| Diametric Capital, LP 0.04% of their portfolio | 750.0k $337.5k | Unchanged |
| Warberg Asset Management LLC 0.08% of their portfolio | 613.4k $276.0k | Added +156.8k |
| ARMISTICE CAPITAL, LLC 0.01% of their portfolio | 500.0k $225.0k | Unchanged |
| PRELUDE CAPITAL MANAGEMENT, LLC 0.01% of their portfolio | 186.6k $84.0k | Unchanged |
| MYDA Advisors LLC 0.02% of their portfolio | 159.8k $71.9k | Reduced -9.1k |
| HEIGHTS CAPITAL MANAGEMENT, INC 0.01% of their portfolio | 90.0k $40.5k | Unchanged |
| ARMSTRONG ADVISORY GROUP, INC 0.00% of their portfolio | 65.9k $29.7k | Unchanged |
| TWO SIGMA SECURITIES, LLC 0.00% of their portfolio | 13.9k $6.2k | Added +2.8k |